An engineered PD-1 receptor-based CAR that binds anti-PD-1 antibodies but not PD-L1 to enhance T-cell functionality

Molecular Therapy: Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles